Report Library
All ReportsPost-EASL KOL Interview
May 29, 2015
Highlights
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
For our disclosures, please read the BioMedTracker Research Standards.
- KOL believes elsbasvir and grazoprevir data will lead to approval and look similar to available drugs on the market (MRK).
- Post-liver transplant data for sofosbuvir and simpeprevir was positive (GLD, JNJ).
- Three DAA combination of -5816,-9857, and sofosbuvir looked good, but most physicians are erring on the side of conservative 12- week treatment regimens except in patients with very low viral loads and little fibrosis (GLD).
- Daclatasvir in combination with Sovaldi will be effective in GT3 patients with or without ribavirin (GLD, BMY).
- KOL treats 85% of patients with Harvoni or sovaldi plus Olysio, and he treats about 15% of patients with Viekira Pak primarily for insurance reasons. He avoids the use of ribavirin if at all possible (BMY, JNJ, ABBV).
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
For our disclosures, please read the BioMedTracker Research Standards.
Indications Covered: |
Hepatitis B (HBV) Treatment (Antiviral)
Hepatitis C (HCV) (Antiviral) Non-Alcoholic Steatohepatitis (NASH) |
Additional Resources: